{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:27:07Z","timestamp":1793827627641,"version":"4.6.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:p>We report a 55-year-old man with metastatic castration-resistant prostate cancer who developed a dramatic \u201cscintigraphic flip\u201d after the second cycle of \u00b9\u2077\u2077Lu-PSMA therapy. Post-therapy SPECT and follow-up \u00b9\u2078F-PSMA PET\/CT showed increased diffuse marrow uptake with paradoxically reduced salivary-gland and liver activity. Despite improved bone pain, reduced analgesic use, and no clinical or laboratory warning signs, this silent redistribution preceded grade III thrombocytopenia and marked anemia, hospitalization for transfusion and supportive care, and death. This case suggests that interval PSMA PET\/CT, particularly in selected high-risk patients, may help identify occult marrow redistribution and support individualized dose adaptation.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006672","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:00:26Z","timestamp":1790154026000},"page":"e1102-e1103","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The \u201cScintigraphic Flip\u201d"],"prefix":"10.1097","volume":"51","author":[{"given":"Daniel Hueng-Yuan","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Kaohsiung Veterans General Hospital"},{"name":"Center for General Education, Cheng Shiu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chieh","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Kaohsiung Veterans General Hospital"},{"name":"Department of Otorhinolaryngology\u2014Head and Neck Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Hsuan Alan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplant Surgery, Kaohsiung Veterans General Hospital, Kaohsiung"},{"name":"Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei"},{"name":"School of Medicine, College of Medicine, National Sun Yat-sen University"},{"name":"Department of Surgery, Division of Urology, Kaohsiung Veterans General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Mechanical and Electro-Mechanical Engineering"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Pin","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Kaohsiung Veterans General Hospital"},{"name":"Center for General Education, Cheng Shiu University"},{"name":"School of Medicine, College of Medicine, National Sun Yat-sen University"},{"name":"Institute of Biomedical Sciences, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00259-026-07823-4","article-title":"Clinical value of per-treatment whole-body single-time-point automated dosimetry for [(177)Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer","volume":"53","author":"Dieudonn\u00e9","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2967\/jnumed.125.270916","article-title":"Linking baseline PSMA PET-derived parameters to toxicity, adverse events, pain, and quality of life in patients treated with [(177)Lu]Lu-PSMA-617: a single-center retrospective study","volume":"67","author":"Murthy","year":"2026","journal-title":"J Nucl Med"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers17142313","article-title":"Feasibility of automated image-based red bone marrow dosimetry for [(177)Lu]Lu-PSMA radiopharmaceutical therapy of metastatic castration-resistant prostate cancer","volume":"17","author":"Rumiantcev","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"3905216","DOI":"10.1155\/2017\/3905216","article-title":"Tumor burden and intraosseous metabolic activity as predictors of bone marrow failure during radioisotope therapy in metastasized prostate cancer patients","volume":"2017","author":"Fiz","year":"2017","journal-title":"Biomed Res Int"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13550-022-00891-1","article-title":"Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression?","volume":"12","author":"Kind","year":"2022","journal-title":"EJNMMI Res"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-025-00816-6","article-title":"Comparison of imaging-based bone marrow dosimetry methodologies and their dose-effect relationships in [177Lu]Lu-PSMA-617 RLT including a novel method with active marrow localization","volume":"13","author":"Peterson","year":"2025","journal-title":"EJNMMI Phys"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","author":"Gaertner","year":"2017","journal-title":"Oncotarget"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:13Z","timestamp":1793826013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006672"}},"subtitle":["A Visual Warning Sign of Impending Hematologic Toxicity"],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006672","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2026-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}